Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis
Brief Summary: The primary purpose for this study is to help answer the following research questions

* The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
* Whether ixekizumab can help participants with Psoriasis.
* How much ixekizumab should be given to participants.


Options:
A: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
B: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CNTO 1275 45 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 45 mg | Arm Label: CNTO 1275 90 mg; Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 90 mg | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: CNTO 1275 45 mg; Assigned to Arm(s): CNTO 1275 45 mg | Intervention Type: DRUG; Name: CNTO 1275 90 mg; Assigned to Arm(s): CNTO 1275 90 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
D: Arm Label: Cohort A: INCB018424 Ruxolitinib 0.5%; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib phosphate cream, Drug: Placebo cream | Arm Label: Cohort B: INCB018424 Ruxolitinib 1.0%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort C: INCB018424 Ruxolitinib 1.5%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene; Type: EXPERIMENTAL; Interventions: Drug: Dovonex® calcipotriene 0.005% | Arm Label: Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate; Type: EXPERIMENTAL; Interventions: Drug: Diprolene® AF betamethasone dipropionate 0.05% cream. | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5% | Intervention Type: DRUG; Name: Dovonex® calcipotriene 0.005%; Assigned to Arm(s): Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene | Intervention Type: DRUG; Name: Diprolene® AF betamethasone dipropionate 0.05% cream.; Assigned to Arm(s): Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5%, Cohort B: INCB018424 Ruxolitinib 1.0%, Cohort C: INCB018424 Ruxolitinib 1.5% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort B: INCB018424 Ruxolitinib 1.0% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort C: INCB018424 Ruxolitinib 1.5%

Answer: B